Adagene
Adagene
ADAG
NASDAQ
1.90
USD
-0.52%
About
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL.
ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 230.7K |
| Three Month Average Volume | 1.0M |
| High Low | |
| Fifty-Two Week High | 4.38 USD |
| Fifty-Two Week Low | 1.2089 USD |
| Fifty-Two Week High Date | 26 Jan 2024 |
| Fifty-Two Week Low Date | 25 Sep 2023 |
| Price and Volume | |
| Current Price | 2.8 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -2.92% |
| Thirteen Week Relative Price Change | -6.57% |
| Twenty-Six Week Relative Price Change | -22.36% |
| Fifty-Two Week Relative Price Change | 64.30% |
| Year-to-Date Relative Price Change | 22.42% |
| Price Change | |
| One Day Price Change | -3.45% |
| Thirteen Week Price Change | 0.00% |
| Twenty-Six Week Price Change | -14.63% |
| Five Day Price Change | -5.08% |
| Fifty-Two Week Price Change | 105.88% |
| Year-to-Date Price Change | 44.97% |
| Month-to-Date Price Change | 9.42% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.59938 USD |
| Book Value Per Share (Most Recent Quarter) | 1.27822 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.59938 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.27822 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.83103 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.4136 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.01853 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.43266 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.72315 USD |
| Normalized (Last Fiscal Year) | -0.43266 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.43266 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.72315 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.43266 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.72315 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.4919 USD |
| Cash Per Share (Most Recent Quarter) | 2.1611 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.41028 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.37726 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -443 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -3,980.34% |
| Pretax Margin (Last Fiscal Year) | -95.27% |
| Pretax Margin (5 Year) | -585.84% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -130.97% |
| Operating Margin (Trailing Twelve Months) | -4,534.81% |
| Operating Margin (5 Year) | -625.19% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -104.61% |
| Net Profit Margin (Trailing Twelve Months) | -3,904.29% |
| Net Profit Margin (5 Year) | -595.78% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 8.96% |
| Tangible Book Value (5 Year) | 9.94% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | 64.33% |
| Revenue Change (Trailing Twelve Months) | -96.40% |
| Revenue Per Share Growth | 63.11% |
| Revenue Growth (5 Year) | 195.64% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -30.24% |
| Total Debt (5 Year) | 56.57% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -309.45% |
| EPS Change (Trailing Twelve Months) | 14.53% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -75,138,630 |
| Net Debt (Last Fiscal Year) | -87,997,010 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 7 |
| Price to Sales (Trailing Twelve Months) | 152 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 19 |
| Long Term Debt to Equity (Most Recent Quarter) | 8 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -28,539,850 |
| Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 31 |
| Total Debt to Equity (Most Recent Quarter) | 36 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -14.13% |
| Return on Assets (Trailing Twelve Months) | -26.98% |
| Return on Assets (5 Year) | -37.42% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -24.66% |
| Return on Equity (Trailing Twelve Months) | -45.70% |
| Return on Equity (5 Year) | -214.27% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -20.87% |
| Return on Investment (Trailing Twelve Months) | -40.42% |
| Return on Investment (5 Year) | -47.32% |